GC
OREX

Guggenheim Capital’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Guggenheim Capital’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,860
Closed -$16K – 3025
2016
Q1 		$16K Sell
2,860
-12,092
-81% -$157K ﹤0.01% 2845
2015
Q4 		$258K Sell
14,952
-1,461
-9% -$34.8K ﹤0.01% 2696
2015
Q3 		$346K Sell
16,413
-922
-5% -$31.6K ﹤0.01% 2540
2015
Q2 		$858K Buy
17,335
+843
+5% +$50.4K ﹤0.01% 2308
2015
Q1 		$1.29M Buy
16,492
+3,735
+29% +$232K ﹤0.01% 2099
2014
Q4 		$773K Sell
12,757
-31,970
-71% -$1.61M ﹤0.01% 2345
2014
Q3 		$1.91M Buy
44,727
+6,408
+17% +$344K ﹤0.01% 1791
2014
Q2 		$2.37M Sell
38,319
-1,602
-4% -$93.2K 0.01% 1669
2014
Q1 		$2.6M Buy
+39,921
New +$2.7M 0.01% 1565
2013
Q3 		– Sell
-31,166
Closed -$1.82M – 3301
2013
Q2 		$1.82M Buy
+31,166
New +$1.92M 0.01% 1595

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Guggenheim Capital's OREX Position: Q2 2016 in Review

Guggenheim Capital sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 2,860 shares — an estimated $16K sold.

Guggenheim Capital first reported a position in OREX in Q2 2013 and held it in 10 quarters. The position peaked at $2.6M in Q1 2014. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

  • Guggenheim Capital reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Guggenheim Capital sold 2,860 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $16K.
  • Guggenheim Capital first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 10 quarters.
  • Guggenheim Capital's Orexigen Therapeutics, Inc. position peaked at $2.6M in Q1 2014.
  • 73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Guggenheim Capital's 13F filing for Q2 2016, filed 15 Aug 2016.